Oasmia Pharmaceutical AB (publ) (OASM) Stock: A Biotechnology Stock That’s Seeing Strong Gains


Oasmia Pharmaceutical AB (publ) (OASM) is working its way for to the top in the market today. The company, one that is focused on the biotech sector, is presently priced at $2.30 after a move up of 5.02% so far in today’s session. When it comes to biotech companies, there are quite a few factors that have the potential to generate price movement in the market. One of the most common is news. Here are the most recent trending headlines associated with OASM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-08-18 02:30AM Oasmia Pharmaceutical AB (publ) Year-end report for the financial year May 1, 2017 April 30, 2018
Jun-05-18 02:30AM Results from Oasmia Pharmaceuticals phase III study have been presented at ASCO annual meeting
May-30-18 11:45AM Nexttobe Extends Loan to Oasmia Pharmaceutical
May-21-18 02:30AM Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
May-17-18 02:30AM Results from Oasmia Pharmaceuticals phase III study will be presented at ASCO annual meeting in June

Nonetheless, when making an investing decision, prospective investors should take a look at much more than just news, especially in the generally speculative biotechnology sector. Here’s what’s happing when it comes to Oasmia Pharmaceutical AB (publ).

How OASM Has Been Trending

Although a single session gain, like what we’re seeing from Oasmia Pharmaceutical AB (publ) may cause excitement in some investors, a single session move alone shouldn’t be the basis of a decision to, or not to, invest in a company. It’s always a good idea to look at trends experienced by the stock for a period longer than a single session. As it relates to OASM, below are the returns on investment that investors have seen:

  • Weekly – In the last week, OASM has seen a price change in the amount of 5.02%.
  • Past 30 Days – The return on investment from Oasmia Pharmaceutical AB (publ) in the past month works out to -22.15%.
  • Past 3 Months – Over the last three months, the company has generated a return that works out to -31.55%
  • Past Six Months – Over the previous 6 months, we have seen a change that equates to -46.14% from the company.
  • Year To Date – Since the close of last year OASM has resulted in a ROI of -23.95%.
  • Full Year – Finally, over the past year, we’ve seen performance amounting to 70.37% from OASM. Throughout this period, the stock has traded at a high of -59.65% and a low of 91.67%.

Ratios To Watch

Looking at a few ratios having to do with a stock can provide investors an understanding of just how dangerous and/or potentially profitable a stock pick may be. Below are some of the important ratios to look at when looking at OASM.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it means that more investors believe that the value of the stock is going to tumble. Across the sector, biotech stocks can have a higher short ratio. On the other hand, we also see a lot of short squeezes in the space. Nonetheless, with regard to Oasmia Pharmaceutical AB (publ), the stock’s short ratio clocks in at 0.04.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure the company’s abilities to pay for its debts when they come due based on current assets or quick assets. In the biotechnology industry, companies are heavily reliant on continued support from investors, the current and quick ratios can be bad. However, quite a few good picks in the biotech industry come with strong quick and current ratios. As it relates to OASM, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets owned by the company. In the case of Oasmia Pharmaceutical AB (publ), the book to share value ratio equates to 0.61.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many early stage biotech companies struggle to keep cash on hand. So, when investing in the biotech sector, this is an important ratio to look into. When it comes to OASM, the cash to share value ratio works out to 0.

How Analysts Feel About Oasmia Pharmaceutical AB (publ)

Although it’s never a smart idea to blindly follow the opinions of analysts, it is a good idea to use their thoughts in order to validate your own due diligence when it comes to making an investment decision in the biotech space. Here are the most recent moves that we’ve seen from analysts with regard to OASM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-12-16 Initiated Rodman & Renshaw Buy $6

What Institutions And Insiders Think Of Oasmia Pharmaceutical AB (publ)

One thing I have learned in my brief period on Earth has been that smart money tends to follow the moves made by big money investors. Usually, investors that are trying to play it relatively safe will watch investments made by institutional investors and those on the inside. So, what does the big money picture look like as it relates to OASM? Here’s the information:

  • Institutional Investors – At the moment, institutional investors own 0.14% of the company. However, it’s worth considering that institutional ownership has seen a move of 0 throughout the last quarter.
  • Investors On The Inside – with regard to insiders, those close to the situation currently hold 0 of the company. Their ownership of the company has moved 0 throughout the past 3 months.

What You Need To Know About Share Counts

Traders and investors seem to be interested in the total numbers of shares both available and outstanding. When it comes to Oasmia Pharmaceutical AB (publ), currently there are 222.22M and there is a float of 51.31M. This means that of the total of 222.22M shares of OASM currently in existence today, 51.31M are available to be traded by the public.

I also like to look at the short percentage of the float. After all, if a high portion of the float is shorted, the overall opinion among traders is that the stock is going to lose value. When it comes to OASM, the percentage of the float that is shorted currently sits at 0.00%. In general, concerning short percent of the float would be considered to be anything over 40%. In my research, I’ve calculated that anything over 26% is usually a a play that could prove to be very risky.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, OASM has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 29.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings play an important part in my ability to learn. Sure, I can dig through social trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at something? If so, write a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here